ABT vs EOLS · P/E 25, rev $44.33B vs rev $266.3M
Abbott Laboratories (ABT) versus Evolus Inc (EOLS) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Evolus Inc (EOLS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported EOLS revenue for 2024-12-31 was $266.3M. Net income was -$50.4M. Revenue was up 31.8% from 2023-12-31 to 2024-12-31. EOLS currently screens at market cap $597.0M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. EOLS currently screens at market cap $597.0M.
Not investment advice. Open the ABT and EOLS stock pages for the full models.
Not investment advice.